Abstract
Twenty-two hospitalized infants with documented RSV lower respiratory tract infection were enrolled in a double-blind placebo-controlled drug efficacy study of the antiviral agent, Ribavirin. Fifteen infants were evaluated for production of specific IgE-RSV in nasopharyngeal secretions at time of admission and at regular intervals during convalescence, up to four months beyond initial presentation. Seven infants were treated with aerosolized Ribavirin for a mean duration of 3.14 days. They ranged in age from 1 mo-12 mos. (median 3 mos) with a male:female ratio of 3:4. Eight infants, during 9 episodes of illness received placebo for mean duration of 5.88 days. They ranged in age from 1-24 mos. (median 3.5 mos) with male:female ratio of 6:2. Atopic family history was positive in 6 of 7 patients treated with drug(85%) as compared to 3/8 in placebo group(38%). One patient in treated group, two in placebo presented with bronchiolitis. RSV infection was documented by indirect immunofluorescent assay for antigen and/or culture positivity. IgE-RSV titers in secretions were quantitated by an ELISA technique. Criteria for a significant response was IgE-RSV titer of 8 or greater by 4 months after initial infection. In the seven treated patients, only two had a significant rise in IgE titer. In contrast, 7 of 8 untreated patients had a significant titer rise. As calculated with the Fisher Exact test, this significant at a p value of 0.033.
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ciardullogeraci, K., Rosner, I., Palumbo, P. et al. 1075 IgE ANTI-RSV SECRETORY IMMUNE RESPONSE IN INFANTS TREATED WITH RIBAVIRIN AEROSOL. Pediatr Res 19, 290 (1985). https://doi.org/10.1203/00006450-198504000-01105
Issue date:
DOI: https://doi.org/10.1203/00006450-198504000-01105
